Evolus, Inc. (EOLS): Price and Financial Metrics

Evolus, Inc. (EOLS): $7.33

-0.01 (-0.14%)

POWR Rating

Component Grades














  • EOLS scores best on the Growth dimension, with a Growth rank ahead of 73.06% of US stocks.
  • The strongest trend for EOLS is in Momentum, which has been heading up over the past 179 days.
  • EOLS's current lowest rank is in the Stability metric (where it is better than 24.08% of US stocks).

EOLS Stock Summary

  • EVOLUS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 90.39% of US listed stocks.
  • With a year-over-year growth in debt of 214.52%, EVOLUS INC's debt growth rate surpasses 93.38% of about US stocks.
  • As for revenue growth, note that EOLS's revenue has grown 63.13% over the past 12 months; that beats the revenue growth of 86.45% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EVOLUS INC are MICT, TREE, XTNT, MBUU, and LICY.
  • Visit EOLS's SEC page to see the company's official filings. To visit the company's web site, go to www.evolus.com.

EOLS Valuation Summary

  • In comparison to the median Healthcare stock, EOLS's price/earnings ratio is 123.28% lower, now standing at -5.4.
  • Over the past 58 months, EOLS's EV/EBIT ratio has gone up 34.8.

Below are key valuation metrics over time for EOLS.

Stock Date P/S P/B P/E EV/EBIT
EOLS 2022-11-25 3.1 14.7 -5.4 -6.0
EOLS 2022-11-23 3.0 14.5 -5.3 -5.9
EOLS 2022-11-22 3.1 14.9 -5.5 -6.1
EOLS 2022-11-21 3.1 15.0 -5.5 -6.1
EOLS 2022-11-18 3.1 14.6 -5.4 -6.0
EOLS 2022-11-17 3.1 14.8 -5.5 -6.1

EOLS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EOLS has a Quality Grade of C, ranking ahead of 44.26% of graded US stocks.
  • EOLS's asset turnover comes in at 0.373 -- ranking 125th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows EOLS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.373 0.630 -3.772
2021-03-31 0.300 0.674 -1.580
2020-12-31 0.271 0.676 -1.214
2020-09-30 0.256 0.735 -0.356
2020-06-30 0.245 0.734 -0.491
2020-03-31 0.216 0.731 -0.603

EOLS Price Target

For more insight on analysts targets of EOLS, see our EOLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.14 Average Broker Recommendation 1.57 (Moderate Buy)

EOLS Stock Price Chart Interactive Chart >

Price chart for EOLS

EOLS Price/Volume Stats

Current price $7.33 52-week high $14.34
Prev. close $7.34 52-week low $5.06
Day low $7.18 Volume 256,800
Day high $7.40 Avg. volume 482,441
50-day MA $8.01 Dividend yield N/A
200-day MA $10.34 Market Cap 412.29M

Evolus, Inc. (EOLS) Company Bio

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is based in Irvine, California.

EOLS Latest News Stream

Event/Time News Detail
Loading, please wait...

EOLS Latest Social Stream

Loading social stream, please wait...

View Full EOLS Social Stream

Latest EOLS News From Around the Web

Below are the latest news stories about EVOLUS INC that investors may wish to consider to help them evaluate EOLS as an investment opportunity.

Evolus Third Quarter 2022 Earnings: Revenues Disappoint

Evolus ( NASDAQ:EOLS ) Third Quarter 2022 Results Key Financial Results Revenue: US$33.9m (up 27% from 3Q 2021). Net...

Yahoo | November 10, 2022

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -18.52% and 8.22%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

Evolus Reports Third Quarter 2022 Results and Provides Business Update

NEWPORT BEACH, Calif., November 08, 2022--Evolus reports financial results for the third quarter ended September 30, 2022 and provides a business update.

Yahoo | November 8, 2022

Evolus to Participate in November Conferences

NEWPORT BEACH, Calif., November 02, 2022--Evolus announces that members of its management team will be participating in two investment conferences in November.

Yahoo | November 2, 2022

Evolus to Report Third Quarter 2022 Results and Provide Business Update

NEWPORT BEACH, Calif., October 25, 2022--Evolus announces that it will report its third quarter 2022 financial results and provide a business update on Tuesday, November 8, 2022.

Yahoo | October 25, 2022

Read More 'EOLS' Stories Here

EOLS Price Returns

1-mo -5.05%
3-mo -19.09%
6-mo -42.46%
1-year 36.50%
3-year -42.28%
5-year N/A
YTD 12.60%
2021 93.75%
2020 -72.39%
2019 2.27%
2018 N/A
2017 N/A

Continue Researching EOLS

Want to see what other sources are saying about Evolus Inc's financials and stock price? Try the links below:

Evolus Inc (EOLS) Stock Price | Nasdaq
Evolus Inc (EOLS) Stock Quote, History and News - Yahoo Finance
Evolus Inc (EOLS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7041 seconds.